T. van Oorschot

发表

Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients

C. Figdor, C. Punt, B. Neyns, 2015, Oncoimmunology.

BDCA1+CD14+ Immunosuppressive Cells in Cancer, a Potential Target?

E. Smits, V. V. Van Tendeloo, I. D. de Vries, 2018, Vaccines.

Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity

W. Oyen, C. Figdor, C. Punt, 2016, Cancer Immunology, Immunotherapy.

Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells

C. Figdor, C. Punt, C. Blank, 2015, Clinical Cancer Research.

Metabolomic and lipidomic signatures associated with activation of human cDC1 (BDCA3+/CD141+) dendritic cells

M. Giera, S. Kostidis, R. Derks, 2021, Immunology.

Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients

C. Figdor, C. Punt, J. D. de Wilt, 2016, Oncoimmunology.

Lamin B2 follows lamin A/C- mediated nuclear mechanics and cancer cell invasion efficacy

P. Friedl, Katarina Wolf, J. Lammerding, 2020, bioRxiv.

Harnessing RNA sequencing for global, unbiased evaluation of two new adjuvants for dendritic-cell immunotherapy

C. Figdor, J. Textor, I. D. de Vries, 2017, Oncotarget.